These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 24118729)

  • 1. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
    Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
    Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of tumor budding detection in stage II colon cancer].
    Liu SJ; Yang XH; Ren JQ; Zhu XJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Aug; 16(8):730-4. PubMed ID: 23980042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
    Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
    Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor budding is an independent predictor of outcome in AJCC/UICC stage II colorectal cancer.
    Betge J; Kornprat P; Pollheimer MJ; Lindtner RA; Schlemmer A; Rehak P; Vieth M; Langner C
    Ann Surg Oncol; 2012 Nov; 19(12):3706-12. PubMed ID: 22669453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma.
    Park KJ; Choi HJ; Roh MS; Kwon HC; Kim C
    Dis Colon Rectum; 2005 Aug; 48(8):1597-602. PubMed ID: 15937624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour budding at invasive margins and outcome in colorectal cancer.
    Kanazawa H; Mitomi H; Nishiyama Y; Kishimoto I; Fukui N; Nakamura T; Watanabe M
    Colorectal Dis; 2008 Jan; 10(1):41-7. PubMed ID: 18078460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of elastic laminal invasion in colon cancer: elastic laminal invasion-positive stage II colon cancer is a high-risk equivalent to stage III.
    Yokota M; Kojima M; Nomura S; Nishizawa Y; Kobayashi A; Ito M; Ochiai A; Saito N
    Dis Colon Rectum; 2014 Jul; 57(7):830-8. PubMed ID: 24901683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.
    Kumar A; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Woods R; Speers C; Cheung WY
    Cancer; 2015 Feb; 121(4):527-34. PubMed ID: 25332117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    Int J Colorectal Dis; 2018 Aug; 33(8):1115-1124. PubMed ID: 29785462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic prognostic markers in stage IIA colorectal cancer: a comparative study.
    Barresi V; Reggiani Bonetti L; Ieni A; Branca G; Tuccari G
    Scand J Gastroenterol; 2016 Mar; 51(3):314-20. PubMed ID: 26554618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor budding and survival after potentially curative resection of node-positive colon cancer.
    Sy J; Fung CL; Dent OF; Chapuis PH; Bokey L; Chan C
    Dis Colon Rectum; 2010 Mar; 53(3):301-7. PubMed ID: 20173477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens.
    Martinez-Ciarpaglini C; Fernandez-Sellers C; Tarazona N; Roselló S; Huerta M; Roda D; Mongort C; Ferrández A; Navarro S; Cervantes A
    Histopathology; 2019 Oct; 75(4):517-525. PubMed ID: 31081121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Landmann RG; Guillem JG; Paty PB; Temple LK; Wong WD; Weiser MR
    Dis Colon Rectum; 2008 May; 51(5):503-7. PubMed ID: 18322753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.
    Höckel M; Hentschel B; Horn LC
    Lancet Oncol; 2014 Apr; 15(4):445-56. PubMed ID: 24656439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients.
    Andreoni B; Chiappa A; Bertani E; Bellomi M; Orecchia R; Zampino M; Fazio N; Venturino M; Orsi F; Sonzogni A; Pace U; Monfardini L
    World J Surg Oncol; 2007 Jul; 5():73. PubMed ID: 17610720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.
    Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
    J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
    Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
    Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
    Wang LM; Kevans D; Mulcahy H; O'Sullivan J; Fennelly D; Hyland J; O'Donoghue D; Sheahan K
    Am J Surg Pathol; 2009 Jan; 33(1):134-41. PubMed ID: 18971777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.